VEGFR2/CD309 antibody

Catalog No. ABIN6265973

Product Details anti-VEGFR2/CD309 Antibody

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This VEGFR2/CD309 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)

Specificity: VEGFR2 Antibody detects endogenous levels of total VEGFR2

Cross-Reactivity: Human, Mouse (Murine), Rat (Rattus)

Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink^TM Coupling Resin (Thermo Fisher Scientific).

Immunogen: A synthesized peptide derived from human VEGFR2

Isotype: IgG

Application Details

Application Notes: WB 1:500-1:2000 IHC 1:50-1:200 IF 1:200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS,  pH 7.4,50 % glycerol.

References for anti-VEGFR2/CD309 antibody (ABIN6265973)

Zhang, Chen, Wang, Yang, Li, Wang, Liu, Ye: "Treatment of diabetes mellitus-induced erectile dysfunction using endothelial progenitor cells genetically modified with human telomerase reverse transcriptase." in: Oncotarget, Vol. 7, Issue 26, pp. 39302-39315, (2018) (PubMed).

Gu: "IL13Rα2 siRNA inhibited cell proliferation, induced cell apoptosis, and suppressed cell invasion in papillary thyroid carcinoma cells." in: OncoTargets and therapy, Vol. 11, pp. 1345-1352, (2018) (PubMed).

Wang, Shen, Liu, Ning, Wu, Huang: "TRIM24 siRNA induced cell apoptosis and reduced cell viability in human nasopharyngeal carcinoma cells." in: Molecular medicine reports, Vol. 18, Issue 1, pp. 369-376, (2018) (PubMed).

Meng, Chen, Lei, Han, Zhong, Wang, Liu, Gao, Zhang, Tan, Liu, Zhou, Sun, Yang: "Hsp90β promotes aggressive vasculogenic mimicry via epithelial-mesenchymal transition in hepatocellular carcinoma." in: Oncogene, (2018) (PubMed).

Wu, Zheng, Bai, Xia, Zhang, Guo: "HMGB1/RAGE axis mediates the apoptosis, invasion, autophagy, and angiogenesis of the renal cell carcinoma." in: OncoTargets and therapy, Vol. 11, pp. 4501-4510, (2018) (PubMed).

Target Details for VEGFR2/CD309

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Alternative Name: VEGFR2 (VEGFR2 Products)

Synonyms: CD309 antibody, FLK1 antibody, VEGFR antibody, VEGFR2 antibody, 6130401C07 antibody, Flk-1 antibody, Flk1 antibody, Krd-1 antibody, Ly73 antibody, VEGFR-2 antibody, sVEGFR-2 antibody, Vegfr-2 antibody, FLK-1 antibody, flk-1 antibody, vegfr-2 antibody, KDR antibody, FLK/KDR antibody, flk1 antibody, flk1b antibody, kdrb antibody, si:busm1-205d10.1 antibody, si:ch211-254j6.1 antibody, si:ch211-278f21.4 antibody, wu:fc31a09 antibody, fk52c05 antibody, flk antibody, kdr antibody, kdra antibody, vegfr2 antibody, vegfr4 antibody, vegr2 antibody, wu:fk52c05 antibody, kinase insert domain receptor antibody, kinase insert domain protein receptor antibody, vascular endothelial growth factor receptor kdr-like antibody, kinase insert domain receptor (a type III receptor tyrosine kinase) antibody, kinase insert domain receptor like antibody, KDR antibody, Kdr antibody, LOC100136647 antibody, kdr antibody, kdrl antibody

Background:

Description: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

Gene: KDR

Molecular Weight: 180kDa

Gene ID: 3791

UniProt: P35968

Pathways: RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling